Purpose: High-dose cisplatin is standard in head and neck cancers. Recently, weekly low-dose platinum alone or with cetuximab has been used. All patients received 70 Gy standard fraction intensity-modulated radiation therapy. We are comparing the former used at the VAMC with the latter regimens used in the department of Oncology at the University of Mississippi. We will present the toxicity, response, patterns of failure, and survival by the use of the different types of chemotherapy.
Conference Coverage
Comparison of Low-Dose Platinum vs High-Dose Platinum vs Cetuximab and Intensity-Modulated Radiation Therapy in Advanced Head and Neck Cancers
Giri S, Kankamedhala M, Suggs JM.
Abstract 7: 2014 AVAHO Meeting
Clinical Topics
-
When cisplatin won’t do, try carboplatin in head and neck cancer -
Is early-onset cancer an emerging global epidemic? -
Despite benefits, extended-interval pembro uptake remains low -
Time to cancer diagnoses in U.S. averages 5 months -
Trends in Palliative Care Utilization and Facility Type for Stage IV Esophageal Cancer: A National Cancer Database Analysis
Digital Edition
Conference Coverage
-
Multiprong strategy makes clinical trials less White -
CBSM phone app eases anxiety, depression in cancer patients -
Huge underuse of germline testing for cancer patients -
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology -
Metronomic chemotherapy performs well in second-line head and neck cancer -
Radiofrequency ablation successful in small thyroid cancers -
A farewell to arms? Drug approvals based on single-arm trials can be flawed -
Time to cancer diagnoses in U.S. averages 5 months -
Pembro/chemo combo fails to improve event-free survival in head and neck cancer -
First drug for desmoid tumors: ‘Impressive’ data for nirogacestat
Question 1 of 5
